Silo Pharma Inc. is making strides in their PTSD treatment with a drug-device study on a microchip-enabled nasal spray system for SPC-15 in partnership with Resyca BV. The study aims to gather final device data for an FDA application, with CEO Eric Weisblum emphasizing the device's potential to bypass the blood-brain barrier for faster and safer therapeutic delivery. Additionally, the company is progressing with other SPC-15 studies, including a toxicology study and a large animal safety trial as requested by the FDA.

Cybin Inc. is making progress in Phase 3 and Phase 2 trials for psychedelic therapeutics targeting mental health conditions, supported by FDA approval. Republican lawmakers like Rep. Morgan Luttrell are advocating for therapeutic use of psychedelics for veterans, while Silo Pharma Inc. recently closed a public offering to fund their research in psychiatric disorders and CNS diseases.

Silo Pharma Inc. has priced a public offering of common stock and warrants to raise $2 million, supporting its work on therapeutic treatments for psychiatric disorders and chronic pain. Meanwhile, NRx Pharmaceuticals, Inc. reported a Q1 net loss decrease, progress on ketamine and bipolar depression treatments, and funding for its psychiatry clinic subsidiary.

Cybin Inc. partners with Thermo Fisher Scientific for manufacturing of CYB003, a deuterated psilocin treatment for major depressive disorder. Silo Pharma Inc. collaborates with Veloxity Labs for bioanalysis supporting a PTSD treatment, while NRx Pharmaceuticals reports financial results post the acquisition of Kadima Neuropsychiatry Institute. All three companies focus on developing psychedelic-based therapeutics for mental health conditions.

Love Yer Brain, part of Iconic Tonics, is collaborating with MoreBetter to study the impact of THC-infused beverages, aiming to provide insights into consumer preferences for alcohol alternatives. Meanwhile, the 7-HOPE Alliance has been established to protect legal access to 7-hydroxymitragynine (7-OHM) and promote responsible usage through science and advocacy efforts.

Cybin Inc. CEO Doug Drysdale will discuss drug development innovation and next-generation mental health treatments at the Milken Institute Global Conference. Meanwhile, Silo Pharma Inc. has reported positive preclinical data for its SP-26 Ketamine Implant for fibromyalgia and filed a patent application for SPC-14 targeting cognitive and neuropsychiatric symptoms in Alzheimer’s disease, showcasing advancements in pain management and cognitive health therapeutics.

In this episode, Atai Life Sciences co-founder and co-CEO Florian Brand discusses the promising initial results from Beckley Psytech's phase 1 trial of ELE-101 for major depressive disorder. ELE-101, an IV formulation of psilocin, aims to shorten treatment duration to two hours, with good tolerance and safety shown in phase one trials. The phase 2 trial is underway with data expected later this year. Brand also highlights the potential benefits of the two-hour treatment model for other compounds in development for depression treatment.

Join neuroscientist Deborah Mash, PhD, on 'Psychedelic Breakthrough Addiction Therapy' as she explores cutting-edge research on breakthrough addiction therapies, focusing on psychedelic medicines like Ibogaine. Dr. Mash, with thirty years of experience in addiction neuroscience, offers insight into groundbreaking therapies with the potential to transform lives. Tune in to CannabisRadio.com to learn more about the renaissance of psychedelic therapy for addiction treatment.

Join host Jonathan Jackson as he speaks with Tryptamine Therapeutics Inc. CEO Jason Carroll about the company's recent debut on the Australian Securities Exchange. Tryptamine Therapeutics is focused on developing an intravenous-infused psilocin formulation for psychedelic therapy, with core programs like TRP-8803 and TRP-8802 showing promising results in trials for conditions like fibromyalgia, IBS, and BED. Backed by a qualified Board and research partnerships, the company is set to begin groundbreaking clinical trials in Australia this quarter.